Successful Treatment of Riehl's Melanosis With Mid-Fluence Q-Switched Nd:YAG 1064-nm Laser

Lasers Surg Med. 2020 Oct;52(8):753-760. doi: 10.1002/lsm.23214. Epub 2020 Jan 17.

Abstract

Background and objectives: Riehl's melanosis is a chronic acquired hyperpigmentation disorder that causes significant cosmetic problems for patients with this condition. Several treatment options, including low-fluence Q-switched Nd:YAG (QSNY) 1064-nm laser treatment, have been attempted with inconsistent results. We aimed to investigate the beneficial effect of mid-fluence QSNY 1064-nm laser in the treatment of Riehl's melanosis.

Study design/materials and methods: A retrospective review was conducted on patients repetitively treated with mid-fluence (3.5-5 J/cm2 with a spot size of 5 mm and a pulse rate of 10 Hz) QSNY 1064-nm laser. Twenty-one patients with Riehl's melanosis were involved. Clinical photographs, treatment parameters, and side effects were reviewed to assess the safety and efficacy of the modality.

Results: The mean age of the patients was 57.00 ±8.2 years, and there were 20 female patients and 1 male patient. The mean number of treatment sessions was 5.95 ± 3.6, and the mean interval between each session was 39.12 ± 13.4 days. After treatment, the mean melasma area and severity index score decreased from 12.53 ± 10.2 to 5.98 ± 5.3. At the final visit, 16 of the 21 (76.1%) patients were considered to have moderately or very much improved. No severe side effects were observed.

Conclusions: Repetitive mid-fluence QSNY 1064-nm laser treatment may be an effective and safe optional modality for Riehl's melanosis. Lasers Surg. Med. © 2020 Wiley Periodicals, Inc.

Keywords: Nd:YAG; Riehl's melanosis; laser treatment; mid-fluence.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Female
  • Humans
  • Hyperpigmentation* / etiology
  • Lasers, Solid-State* / therapeutic use
  • Low-Level Light Therapy*
  • Male
  • Melanosis* / radiotherapy
  • Middle Aged
  • Retrospective Studies
  • Treatment Outcome